Drug Trial Radar · NCT07765888
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Mar 10, 2028
Study completion Jun 2, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated. * This study is seeking participants who: Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20. Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.
Conditions
- Atopic Dermatitis
Interventions
TilrekimigDrug
Subcutaneous Injections at required timepoints
PlaceboDrug
Subcutaneous Injections at required timepoints
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placeboTime frame: Week 16
- Difference in the proportion of Validated Investigator Global Assessment (vIGA)-AD™ 0/1 responders between tilrekimig versus placeboTime frame: Week 16
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center
Birmingham, Alabama · Recruiting
ORSO Health
Scottsdale, Arizona · Recruiting
Kern Research, Inc.
Bakersfield, California · Recruiting
First OC Dermatology Research Inc
Fountain Valley, California · Not yet recruiting
Northridge Clinical Trials
Northridge, California · Recruiting
University Clinical Trials, Inc
San Diego, California · Recruiting
Focus Clinical Research
West Hills, California · Not yet recruiting
Pediatric Skin Research
Miami, Florida · Recruiting
AllerVie Clinical Research
Panama City, Florida · Recruiting
GCP Research , Global Clinical Professionals
St. Petersburg, Florida · Recruiting
Marietta Dermatology Clinical Research, Inc.
Marietta, Georgia · Recruiting
Aeroallergy Research Laboratories of Savannah, Inc
Savannah, Georgia · Recruiting
Red River Research Partners LLC
Fargo, North Dakota · Recruiting
Derm Texas
Dallas, Texas · Recruiting
Stryde Research-Epiphany Dermatology
Southlake, Texas · Recruiting
Innovaderm Research Inc
Montreal, Quebec, Canada · Recruiting
Charme Clinique
Matsudo, Chiba, Japan · Recruiting
Miyata Dermatology Clinic
Matsudo, Chiba, Japan · Recruiting
Shibaki Dermatology Clinic
Teine-ku, Hokkaido, Japan · Not yet recruiting
Aile Home Clinic Nagaoka
Nagaoka, Niigata, Japan · Recruiting
Osaka Metropolitan University Hospital
Osaka, Osaka, Japan · Not yet recruiting
Dermatology and Ophthalmology Kume Clinic
Sakai, Osaka, Japan · Recruiting
NTT Medical Center Tokyo
Shinagawa, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.